Suppr超能文献

[肺淋巴管平滑肌瘤病(LAM)]

[Pulmonary lymphangioleiomyomatosis (LAM)].

作者信息

Theegarten D, Hager T

机构信息

Institut für Pathologie, Universitätsklinikum Essen, Hufelandstr. 55, 44145, Essen, Deutschland.

出版信息

Pathologe. 2021 Feb;42(1):35-39. doi: 10.1007/s00292-020-00901-w. Epub 2021 Jan 8.

Abstract

Lymphangioleiomyomatosis (LAM) is a rare lung disease that mostly occurs in female patients. A total of 200-400 people are assumed to be infected in Germany. A sporadic form and a form associated with the tuberous sclerosis complex (TSC) can be separated. Mutations of the TSC‑1 and TSC‑2 genes are relevant. Morphologically, pulmonary multicysts and marginal micronodal proliferations of LAM cells are characteristic. Combinations with renal angiomyolipoma are typical and, in cases with TSC glioma, facial angiofibroma and ungual fibroma are seen. Prognosis is favorable (10-year survival: 80%) and with the use of mTORC1 inhibitors it could be improved. Lung transplantation can be considered in some cases.

摘要

淋巴管平滑肌瘤病(LAM)是一种罕见的肺部疾病,主要发生于女性患者。据推测,德国共有200 - 400人感染此病。可分为散发性形式和与结节性硬化症(TSC)相关的形式。TSC-1和TSC-2基因的突变与之相关。在形态学上,肺部多囊和LAM细胞的边缘微结节增殖具有特征性。与肾血管平滑肌脂肪瘤合并较为典型,在伴有TSC的病例中,可见脑胶质瘤、面部血管纤维瘤和甲下纤维瘤。预后良好(10年生存率:80%),使用mTORC1抑制剂可改善预后。在某些情况下可考虑肺移植。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验